Financial Ratios

CHEMO-PHARMA LABORATORIES LTD.

NSE : NABSE : 506365ISIN CODE : INE320M01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE84.001.5 (+1.82 %)
PREV CLOSE ( ) 82.50
OPEN PRICE ( ) 80.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 139
TODAY'S LOW / HIGH ( )80.20 84.00
52 WK LOW / HIGH ( ) 27.1787
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)0.323.731.672.771.38
   CEPS(Rs)0.403.861.832.921.41
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)77.3577.0373.3071.6368.86
   Tax Rate(%)35.38-53.4419.5115.9818.98
Margin Ratios
   Core EBITDA Margin(%)
   EBIT Margin(%)
   Pre Tax Margin(%)
   PAT Margin (%)
   Cash Profit Margin (%)
Performance Ratios
   ROA(%)0.424.992.273.882.00
   ROE(%)0.414.972.303.942.02
   ROCE(%)0.743.242.864.692.50
   Asset Turnover(x)0.000.000.000.000.00
   Sales/Fixed Asset(x)0.000.000.000.000.00
   Working Capital/Sales(x)0.000.000.000.000.00
Efficiency Ratios
   Fixed Capital/Sales(x)
   Receivable days
   Inventory Days
   Payable days
Valuation Parameters
   PER(x)126.5211.0610.712.357.71
   PCE(x)99.0810.709.772.227.54
   Price/Book(x)0.520.540.240.090.15
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)
   EV/Core EBITDA(x)-0.710.02-24.47-15.14-5.30
   EV/EBIT(x)-0.820.03-26.35-15.85-5.39
   EV/CE(x)-0.010.00-0.74-0.71-0.13
   M Cap / Sales
Growth Ratio
   Net Sales Growth(%)
   Core EBITDA Growth(%)-74.1514.69-35.2999.15-66.13
   EBIT Growth(%)-76.3917.43-37.1193.76-66.59
   PAT Growth(%)-91.55123.91-39.76101.25105.00
   EPS Growth(%)-91.55123.92-39.77101.25105.00
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.000.00
   Current Ratio(x)306.6758.17187.5340.3293.39
   Quick Ratio(x)306.6758.17187.5340.3293.39
   Interest Cover(x)6.631747.001415.842028.63467.57
   Total Debt/Mcap(x)0.000.000.000.000.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.